Denosumab

地舒单抗

Report date: 2026/05/20 20:02:01
First In Class

Base Information

Drug NameDenosumab
Drug Alias Name狄诺塞麦Denosumabum德尼单抗狄迪诺塞麦迪诺舒单抗 +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone metastasesGlucocorticoid-induced osteoporosisMetastatic breast cancer +[57] 
Global Approved IndicationsOsteoporosis, PostmenopausalBone NeoplasmsMultiple Myeloma
Approved Indications in ChinaOsteoporosis, Postmenopausal
Original Approved Country/TerritoryEU
Original Approved Date2010/05/26
Country/TerritoryCzechiaBelgiumBulgaria +[52] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesLambda Therapeutic Research LtdSwiss Cancer InstituteWuhan Union Hospital +[13] 
Inactive CompaniesChinese University Of Hong Kong (Cuhk)University Of ManitobaJules Bordet Institute +[13] 
Active IndicationsBone metastasesGlucocorticoid-induced osteoporosisMetastatic breast cancer +[26] 
Inactive IndicationsHormone-Resistant Prostate NeoplasmsSolid tumoursBreast Diseases +[31] 

Other Information

ATC CodeM05BX04
Related LinksWikipediaDrugBankKEGG